Potential implications of CYP3A4, CYP3A5 and MDR-1 genetic variants on the efficacy of Lopinavir/Ritonavir (LPV/r) monotherapy in HIV-1 patients.

MLA

Berno, Giulia, et al. “Potential Implications of CYP3A4, CYP3A5 and MDR-1 Genetic Variants on the Efficacy of Lopinavir/Ritonavir (LPV/r) Monotherapy in HIV-1 Patients.” Journal of the International AIDS Society, vol. 17, no. 4 Suppl 3, Nov. 2014, p. 19589. EBSCOhost, https://doi.org/10.7448/IAS.17.4.19589.

APA

Berno, G., Zaccarelli, M., Gori, C., Tempestilli, M., Pucci, L., Antinori, A., Perno, C. F., Pucillo, L. P., & D’Arrigo, R. (2014). Potential implications of CYP3A4, CYP3A5 and MDR-1 genetic variants on the efficacy of Lopinavir/Ritonavir (LPV/r) monotherapy in HIV-1 patients. Journal of the International AIDS Society, 17(4 Suppl 3), 19589. https://doi.org/10.7448/IAS.17.4.19589

Chicago

Berno, Giulia, Mauro Zaccarelli, Caterina Gori, Massimo Tempestilli, Luigia Pucci, Andrea Antinori, Carlo Federico Perno, Leopoldo Paolo Pucillo, and Roberta D’Arrigo. 2014. “Potential Implications of CYP3A4, CYP3A5 and MDR-1 Genetic Variants on the Efficacy of Lopinavir/Ritonavir (LPV/r) Monotherapy in HIV-1 Patients.” Journal of the International AIDS Society 17 (4 Suppl 3): 19589. doi:10.7448/IAS.17.4.19589.